GNCA GENOCEA BIOSCIENCES

Genocea Announces Upcoming Presentations at SITC 2018

Genocea Announces Upcoming Presentations at SITC 2018

Posters showcase ability of ATLAS™ platform to identify neoantigens for inclusion in and exclusion from personalized immunotherapies

CAMBRIDGE, Mass., Oct. 09, 2018 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing personalized cancer immunotherapies, today announced the titles and times of its presentations at the upcoming 33rd Annual Meeting of The Society for Immunotherapy of Cancer () taking place November 7 to 11, 2018 at the Walter E. Washington Convention Center in Washington, D.C.

The following posters will be located in Poster Hall E. While the Poster Hall will be open on Friday, November 9 from 8 a.m. – 8 p.m. and Saturday, November 10 from 8 a.m. – 8:30 p.m., the three Genocea posters will be presented simultaneously on Saturday, November 10 from 12:20 – 1:50 p.m. and 7:00 – 8:30 p.m.

Poster Number: P154

Title: Empiric profiling of neoantigen-specific T cell responses in NSCLC patients with ATLAS™ reveals unexpected neoantigen and inhibitory antigen profiles

Poster Number: P166

Title: Ex vivo ATLAS-identified inhibitory neoantigens promote mouse melanoma tumor progression

Poster Number: P174

Title: A phase 1/2a study to evaluate the safety, tolerability, immunogenicity, and anti-tumor activity of GEN-009 adjuvanted neoantigen vaccine in adult patients with selected solid tumors

Per SITC policy, full abstracts are embargoed until 8 am ET on November 6, 2018.

About Genocea Biosciences, Inc.

Genocea's mission is to help conquer cancer by designing and delivering targeted cancer vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has developed ATLAS™, its proprietary technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. Genocea is currently studying the safety, immunogenicity, and efficacy of its lead neoantigen cancer vaccine, GEN-009, in a Phase 1/2a clinical trial. For more information, please visit .

Contact:

Jennifer LaVin

617-715-6687

EN
09/10/2018

Underlying

GNCAGENOCEA BIOSCIENCES

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on GENOCEA BIOSCIENCES

 PRESS RELEASE
Free
GNCA GENOCEA BIOSCIE...

Genocea Announces Wind Down of Operations and Delisting From NASDAQ

Genocea Announces Wind Down of Operations and Delisting From NASDAQ CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, announced that its Board of Directors voted to wind down the Company’s ongoing operations and terminate the Company’s remaining employees except those deemed necessary to complete an orderly wind down. On May 23, 2022, the Company delivered formal notice to The Nasdaq Stock Market, Inc. of its intent to voluntarily delist its Common Stock from the ...

May 24, 2022 1 EN
 PRESS RELEASE
Free
GNCA GENOCEA BIOSCIE...

Genocea Initiates Restructuring and Announces Plan to Explore Strategi...

Genocea Initiates Restructuring and Announces Plan to Explore Strategic Alternatives CAMBRIDGE, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and has engaged professional advisors, including an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of the Company,...

April 28, 2022 1 EN
 PRESS RELEASE
Free
GNCA GENOCEA BIOSCIE...

Genocea Biosciences to Host Investor Webinar

Genocea Biosciences to Host Investor Webinar CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced details for a planned investor webinar to coincide with the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13. The presentation, beginning at 4:30 PM EDT on Friday, April 8th will be followed by a Q&A session. The Genocea team will discuss , including late-breaking data from the TiTAN™ clinical trial for the neoantigen-targeted peripher...

April 4, 2022 1 EN
 PRESS RELEASE
Free
GNCA GENOCEA BIOSCIE...

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conferenc...

Genocea to Present at the 32nd Annual Oppenheimer Healthcare Conference CAMBRIDGE, Mass., March 14, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today announced that Chip Clark, President and Chief Executive Officer, will present a corporate overview at the 32nd Annual Oppenheimer Healthcare Conference on Thursday, March 17th at 8:40 A.M. ET. A live webcast of the presentation will be available under the "Events and Presentations" tab of the investor relations section of the Genocea website at . A replay of t...

March 14, 2022 1 EN
 PRESS RELEASE
Free
GNCA GENOCEA BIOSCIE...

Genocea Provides Fourth Quarter 2021 Corporate Update

Genocea Provides Fourth Quarter 2021 Corporate Update Initial GEN-011 clinical trial data to be presented at AACR Conference call today at 8:30 a.m. ET CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Genocea Biosciences, Inc. (Nasdaq: GNCA), a biopharmaceutical company developing next-generation neoantigen immunotherapies, today provided a business update for the fourth quarter ended December 31, 2021. GEN-011 TiTAN™ trial update Genocea is conducting the Phase I/2a TiTAN clinical trial for its lead program GEN-011, a neoantigen-targeted peripheral T cell (NPT) therapy ca...

March 10, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch